Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07062549
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
First-in-Human Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions
Renal Cell Carcinoma (Kidney Cancer)
Interventions
111In-XYIMSR-01
Updated 1 time since 2025 Last updated: Jul 17, 2025 Started: Jan 26, 2022 Primary completion: Jul 31, 2027 Completion: Jul 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Renal Cell Carcinoma (Kidney Cancer) and is currently actively recruiting participants. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins leads this study, which shows 1 recorded version since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .